CN102497888B - 用于成像的全氟化合物 - Google Patents

用于成像的全氟化合物 Download PDF

Info

Publication number
CN102497888B
CN102497888B CN201080041769.8A CN201080041769A CN102497888B CN 102497888 B CN102497888 B CN 102497888B CN 201080041769 A CN201080041769 A CN 201080041769A CN 102497888 B CN102497888 B CN 102497888B
Authority
CN
China
Prior art keywords
imaging
perfluoro
contrast agent
use according
butylcyclohexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080041769.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102497888A (zh
Inventor
M·伊尔迪里姆
H·格吕尔
R·M·J·N·拉默里奇斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Publication of CN102497888A publication Critical patent/CN102497888A/zh
Application granted granted Critical
Publication of CN102497888B publication Critical patent/CN102497888B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080041769.8A 2009-07-31 2010-07-21 用于成像的全氟化合物 Expired - Fee Related CN102497888B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166955.6 2009-07-31
EP09166955 2009-07-31
PCT/IB2010/053321 WO2011013038A2 (en) 2009-07-31 2010-07-21 Perfluoro compounds for use in imaging

Publications (2)

Publication Number Publication Date
CN102497888A CN102497888A (zh) 2012-06-13
CN102497888B true CN102497888B (zh) 2014-10-29

Family

ID=43304070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080041769.8A Expired - Fee Related CN102497888B (zh) 2009-07-31 2010-07-21 用于成像的全氟化合物

Country Status (5)

Country Link
US (1) US20120128589A1 (enExample)
EP (1) EP2459235B1 (enExample)
JP (2) JP5840609B2 (enExample)
CN (1) CN102497888B (enExample)
WO (1) WO2011013038A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101906574B1 (ko) * 2013-01-15 2018-10-10 주식회사 엘지생활건강 발수성을 가지는 칫솔모 및 이를 포함하는 칫솔
CN118859065A (zh) * 2024-07-01 2024-10-29 中国科学院精密测量科学与技术创新研究院 一种利用凝血级联放大提升19f mri肿瘤信噪比的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185760A1 (en) * 2002-03-26 2003-10-02 Gregory Lanza Paramagnetic particles that provide improved relaxivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4453028A (en) * 1982-03-29 1984-06-05 Lagow Richard J Perfluorinated compounds with cyclohexyl groups
US5236694A (en) 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5571498A (en) 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
US6167887B1 (en) * 1997-11-21 2001-01-02 Synthetic Blood International, Inc. Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6574497B1 (en) * 2000-12-22 2003-06-03 Advanced Cardiovascular Systems, Inc. MRI medical device markers utilizing fluorine-19
US8777889B2 (en) * 2004-06-15 2014-07-15 Ceramatec, Inc. Apparatus and method for administering a therapeutic agent into tissue
EP1817098A1 (en) 2004-10-29 2007-08-15 Koninklijke Philips Electronics N.V. Method and apparatus for the preparation of dispersions of particles for use as contrast agents in ultrasound imaging
WO2007127958A2 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
JP5366824B2 (ja) * 2006-12-19 2013-12-11 コーニンクレッカ フィリップス エヌ ヴェ ２次元ビデオの３次元ビデオへの変換方法及びシステム
EP2130058B1 (en) 2007-03-19 2013-05-15 Koninklijke Philips Electronics N.V. Fast magnetic resonance spectroscopic imaging
EP1985312A1 (en) 2007-04-25 2008-10-29 Koninklijke Philips Electronics N.V. T1 reduction in 19F magnetic resonance imaging (MRI)
KR101005561B1 (ko) * 2008-06-21 2011-01-05 한국생명공학연구원 광학특성 나노입자 및 퍼플루오로카본으로 구성된 나노에멀젼을 이용한 다중모드 조영 방법
CN102395548A (zh) * 2009-04-15 2012-03-28 奥斯金生医公司 全氟化碳类乳液

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185760A1 (en) * 2002-03-26 2003-10-02 Gregory Lanza Paramagnetic particles that provide improved relaxivity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Effect of Isovolemic Hemodilution with Oxycyte○R, a Perfluorocarbon Emulsion, on Cerebral Blood Flow in Rats;Zhong-jin Yang et al.;《PLoSONE》;20080430;第3卷;第e2010页 *
THE SYNTHESIS OF HIGHLY FLUORINATED ALKYLCYCLOHEXANES FOR USE AS OXYGEN CARRIERS AND THE 19F AND 13C NMR SPECTRA OF ALKYLCYCLOHEXANES;Wen-Huey LIN et al.;《 Journal of Fluorine Chemistry》;19901231;第50卷;第345-358页 *

Also Published As

Publication number Publication date
CN102497888A (zh) 2012-06-13
JP5840609B2 (ja) 2016-01-06
EP2459235B1 (en) 2014-04-23
JP2013500959A (ja) 2013-01-10
JP2016029098A (ja) 2016-03-03
WO2011013038A2 (en) 2011-02-03
EP2459235A2 (en) 2012-06-06
US20120128589A1 (en) 2012-05-24
WO2011013038A3 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
Ehlerding et al. Big potential from small agents: nanoparticles for imaging-based companion diagnostics
Hsu et al. Nanomaterial-based contrast agents
Bunzen et al. Recent advances in metal–organic frameworks for applications in magnetic resonance imaging
Li et al. Multimodality imaging in nanomedicine and nanotheranostics
Cha et al. Functional mesoporous silica nanoparticles for bio‐imaging applications
Kim et al. Recent development of inorganic nanoparticles for biomedical imaging
Marasini et al. Integration of gadolinium in nanostructure for contrast enhanced‐magnetic resonance imaging
Park et al. Towards clinically translatable in vivo nanodiagnostics
Smith et al. Nanomaterials for in vivo imaging
Terreno et al. Challenges for molecular magnetic resonance imaging
Kunjachan et al. Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects
Hahn et al. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives
Wang et al. Magnetically decorated multiwalled carbon nanotubes as dual MRI and SPECT contrast agents
US8580230B2 (en) Materials and methods for MRI contrast agents and drug delivery
Hequet et al. Fluorinated MRI contrast agents and their versatile applications in the biomedical field
Li et al. 19F MRI nanotheranostics for cancer management: progress and prospects
Zhang et al. Renal clearable magnetic nanoparticles for magnetic resonance imaging and guided therapy
Bonlawar et al. Targeted nanotheranostics: integration of preclinical MRI and CT in the molecular imaging and therapy of advanced diseases
Shaghaghi et al. Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET
Jiang et al. Relaxivity enhancement of hybrid micelles via modulation of water coordination numbers for magnetic resonance lymphography
Liu et al. Nanoprobes for PET/MR imaging
Chen Nanoplatform-based molecular imaging
Calle et al. Advanced contrast agents for multimodal biomedical imaging based on nanotechnology
Yim et al. MRI Contrast Agent‐Based Multifunctional Materials: Diagnosis and Therapy
Sawhney et al. Nanotechnology at the forefront of liver cancer diagnosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20190721

CF01 Termination of patent right due to non-payment of annual fee